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Abstract
There has been remarkable progress in identifying the perplexity of genomic
landscape of cancer over the past two decades, providing us a brand new way to
understand cancer and anti-cancer drugs. However, it is extremely expensive and
time-consuming to develop anti-cancer drugs, and the diversity of cancer genomic
features and drug molecular features renders it considerably difficult to customize
therapy strategy for patients. In order to facilitate the discovery of new anti-cancer
drugs and the selection of drugs to provide personalized treatment strategy, we seek
to predict the response of different anti-cancer drugs with deep learning models.
We test our model on breast cancer cell lines at first, and then generalize our method
on pan-cancer dataset. We incorporate 2 kinds of essential information for anti-
cancer drug response prediction into our model, namely gene expression data of
cancer cell lines and drug molecular data. In order to extract representative features
from these unlabeled data, we propose variational autoencoder (VAE) which has
been proved to be very powerful in unsupervised learning. Our model encode
gene expression data and drug molecular data with geneVAE model and rectified
Junction Tree variational autoencoder[1] (JTVAE) model respectively, and process
the encoded features with a Multi-layer Perceptron (MLP) model to produce a
final prediction. We reach an average coefficient of determination (R2 = 0.83)
in predicting drug response on breast cancer cell lines and an average R2 > 0.84
on pan-cancer cell lines. We further explore the latent representations encoded by
geneVAE and JTVAE model, and the results show these models are robust and can
preserve critical features of original data.
1 Introduction
With the development of molecular biology, the study of cancer genomics has enabled scientists
to develop anti-cancer drugs according to cancers’ genomic features. These drugs are used widely
and have great significance in the therapy of cancer treatment nowadays. However, it is extremely
expensive and time-consuming to develop anti-cancer drugs, and the diversity of cancer genomic
features and drug molecular features makes it considerably difficult to customize therapy strategy for
patients. In order to facilitate the discovery of new anti-cancer drugs and the selection of drugs to
provide personalized treatment strategy, an accurate prediction of anti-cancer drug response is in an
urgent need. Some researchers study drug molecular embeddings[1, 2, 3, 4, 5, 6] and cancer genomic
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data [7, 8, 9, 10] separately, while some others combine them in deep neural networks[11, 12, 13, 14]
to predict drug efficacy. Nevertheless, most of these methods focus on the analysis of original data,
which might influence the performance because of a large mount of redundant information in these
data.
There exists many ways to extract representative features from drug molecular data and cancer
genomic data. According to supervised learning methods, random forest is able to list the importance
of each gene, which can help us filter genes at the very first step. However it will encounter the
problems when meeting data with no labels, such as the Cancer Cell Line Encyclopedia (CCLE)
datasets that we want to explore. Some unsupervised learning methods, such as principal component
analysis (PCA) , independent component analysis (ICA) and manifold learning based t-distributed
stochastic neighbor embedding (t-SNE) are common in analyzing medical data where feature numbers
are numerous and features are with no labels. However, they are primarily for 2D visualization in
most cases and might lose many important information when compressing data into high dimensional
latent features. If situated in a higher dimension, they do not perform well at all and we cannot judge
its performance intuitively by visualizing latent space[15].
To extract features from a huge amount of unlabeled genomic data , we take advantage of variational
autoencoder(VAE)[16], which has achieved great success in the field of unsupervised learning
of complex probability distribution. The amazing ability of VAE models to capture probabilistic
distribution of latent features could enable more complete analysis of genomic data, making it
easier to predict the response of anti-cancer drugs when they are used in specific cancer cell lines.
As for anti-cancer drugs, we adopt Junction Tree VAE model, transforming their molecular graph
into junction trees by functional group split to extract their low dimensional features. Finally, we
implement a fully connected neural network to combine the extracted features to produce the final
result, IC50 value of the anti-cancer drug used against the cancer cell line.
Additionally, as researches on cancer are going much deeper than ever before, various kinds of
information are available to make a more accurate prediction of anti-cancer drug response. For
example, Cancer Genomic Census (CGC) [17] dataset, containing a number of genes highly relevant
with cancer, could be used to curate a gene subset from cancer genomic data, removing a significant
amount of useless information.
Present work Our present work focuses on learning latent embeddings of original data with
variational autoencoders(VAE) and using latent vectors to accomplish further tasks. Our work includes
two VAE models, one for cancer genomic data input and the other for drug molecular sequence
data input. We choose gene expression level as cancer genomic data and SMILES representation as
drug molecular data. Our drug response model is based on a deep neural network, producing IC50
value as final prediction. We choose coefficient of determination metrics(R2) and root mean squared
error(RMSE) as metrics to evaluate our drug response prediction. The datasets that we adopt are
Cancer Cell Line Encyclopedia(CCLE) gene expression dataset, Cancer Gene Census (CGC) dataset,
ZINC molecular structure dataset and GDSC drug response dataset [8, 18]. We firstly test our model
on breast cancer cell lines and then generalize it on pan-cancer cell lines. We also explore the latent
representations encoded by geneVAE and JTVAE, to prove the robustness of our model. While our
present work is based on VAE, more ideas can be found in our future work part that we will attempt
to realize.
2 Related work
Dimensionality reduction on features Reducing feature numbers or encoding features into lower
dimensions is common in those projects that use feature engineering to make predictions or analyze
clustering effects. Supervised learning methods can help select gene subsets which are the most
related to the research task, such as random forest with feature importance about gene in RNA
sequence case-control studies[19] and support vector machines (SVM) with double RBF-kernels
to filter irrelevant gene features[20]. Unsupervised learning methods, such as principal component
analysis(PCA) and hierarchical learning can help explain the genes’ group features and use certain
PCs or hierarchical relationship to a lower dimension mapping space[21]. Our idea is to compare
traditional unsupervised learning methods with the VAE since our CCLE and ZINC dataset are
unlabeled. We try to find the difference between each latent space and talk about the feasibility of
using VAE.
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Figure 1: Variational autoencoders on gene expression data. In this research we pay much attention
on its latent space and use latent vector to make predictions. We show the first 20 genes in each
breast cancer cell line specifically(51 breast cancer cell lines in total). The feasibility of VAE can be
explained by its high similarity from raw gene expression data to its reconstructed one.
Variational auto-encoders on gene expression A plethora of works have been done on encoding
important features from gene expression data. The core idea behind feature extraction is how to
learn latent vectors effectively from input embedding. Usually, multi-layer perceptrons can avoid
the curse of dimensionality and simply encode gene features from the input layer[11, 7, 12]. An
encoder-decoder structure[7] extends a multi-layer perceptron, which considers more about the
reconstruction of original data. The bottleneck layer represents latent information from this kind
of autoencoder. Recently, variational autoencoder(VAE)[16] has appeared frequently in pre-trained
models that encode gene expression data [9, 10, 22]. These studies primarily focus on latent space
representation based on maximizing likelihood of gene distribution. As for gene expression data, we
also take advantage of VAE model. We implement a simple deep-neural-network based VAE to form
a pre-trained encoder, which will be fit into the combined MLP drug prediction network together
with JTVAE model.
Representation learning on graph for drug molecular features Graph features can be en-
coded by deep learning methods, such as convolutional neural network(CNN), recurrent neural
network(RNN) and message passing neural network(MPNN)[23, 24, 2]. Besides, variational autoen-
coder(VAE) is also widely used in graph generation and graph encoders[3, 4, 25, 5, 26]. In order
to avoid generating nodes one by one, which is often of non-sense in drug design, a method that
combined tree encoder with graph encoder was proposed[1]. It treats functional groups as nodes
for broadcasting. Also, attention mechanism are applied to RNN and CNN models[12, 13], which
are frequently used in natural language processing and computer vision tasks. They learn attention
weights by multihead-attention or self-attention with softmax operation in order to forget certain
unimportant genes or drugs during propagation. Among all these studies, we choose junction tree
variational autoencoder(JTVAE) as our pre-trained model on encoding drug structures. Although
attention mechanism is popular in recent works, training such a transformer takes time and we have
included it in our future work.
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Figure 2: We show the structure of the original junction tree variational autoencoder(VAE), which is
proposed by Jin et.al in 2018. The model has been split into two parts: tree and graph reconstruction.
The important thing about JTVAE is the tree structure expanded from functional group apart from
usual graph node generation by neighbours. Since we consider about the latent vectors both from
graph and its tree structure, we supplement some codes and use a different SMILES expression list to
the original project to make sure that we extract the latent vectors correctly.
Figure 3: After we extract both drug and gene latent vectors from individual VAE model, we let
them pass through single MLP model to reduce dimension again, following by the concatenated
operation, finally we build a multi-layer perceptron to predict drug response IC50. In our research, we
take support vector machine regressor as one of our baseline models since it’s easy to train and also
intuitive. Another baseline model is based on dense deep neural network, from input gene expression
data(with encoded drug latent vectors) directly to output drug response data.
Drug response prediction methods Supervised learning methods are useful to predict drug re-
sponse with encoded information. Support vector regression(SVR) and random forest regressor are
basic algorithms to perform regression. Recently, deep neural network methods have been popular
in the drug prediction network[11, 7, 12, 13]. Our own drug prediction network is also based on
deep neural network but with some modifications. It is worth noticing that unlike some former works
where models are restricted in several specific drugs [27, 28, 29], our model could take as input
merely any organic compounds as anti-cancer drug as long as their functional groups are included in
the training set of JTVAE, so it could serve as an effective method to reduce the cost of developing
new drugs.
3 Materials and Methods
In this section we show the strategy we adopt to process the datasets and how we implement our model.
Our model takes as input the gene expression data of a cancer cell line and SMILES representation of
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an anti-cancer drug, and produces a drug response prediction in terms of ln(IC50) . It consists of a
VAE to extract features from gene expression data, a JTVAE to extract features from drug molecular
data and an MLP model to produce a final prediction.
3.1 Data
Gene expression data We obtain gene expression data of 1021 cancer lines with 57820
genes provided by the Cancer Cell Line Encyclopedia (CCLE)[8]. Each cell line be-
longs to a specific cancer type. Specifically, we choose breast cancer as our research ob-
ject primarily, and then generalize our model on pan cancer cell lines. After filtering by
key word token [BREAST], we select 51 breast cancer cell lines from this dataset, which
are [AU565_BREAST],[BT20_BREAST],[BT474_BREAST],...,[ZR7530_BREAST]. Gene ex-
pression data is given by G∈ Rg×c, where g is the number of genes and c is the number of cancer
cell lines. The elements of matrix G are log2(tpm + 1), where tpm is transcriptome per million
(tpm) value of the gene in the corresponding cell line. Moreover, we access the Cancer Genomic
Census (CGC) dataset[11], which classifies different genes into two tiers. One tier is for the genes
that are closely associated with cancers and have a high probability to mutate in cancers that change
the activity of the gene product. The other tier includes genes that play a strong indicated role in
cancer but show little evidence. Genes in both tiers are highly relevant with cancer, and we take all of
these genes in our research. We select 51 breast cancer cell lines from CCLE data set and remove
expression data of genes which are not in CGC dataset. Each gene expression entrance with a mean
of µ which is less than 1 or standard deviation σ which is less than 0.5 are also removed for their
little relevance with cancer cell lines [7]. Eventually, we get gene expression data of 597 genes in 51
breast cancer cell lines.
Anti-cancer drug molecular structure data In this research, we have prepared ZINC dataset for
molecular structure data of organic compounds to train the JTVAE model. Molecular structure data is
given in simplified molecular-input line entry system (SMILES) strings. SMILES representation is
often used in defining drug structures[11, 12, 13, 1, 3, 4, 5, 14]. They are widely used as inputs in
drug structure prediction tasks. Also, SMILES representation is easier for us to get embeddings from
vocab parsing library that we have generated. From ZINC data set, we select 10, 000 SMILES strings
to train our JTVAE model. The number of trained SMILES strings that we choose is far beyond the
actual number of 222 drugs in processed GDSC dataset. The reason is that we would like to see a
better generalization on all drug structures instead of drugs on specific cancer types.
Drug response data Drug response data is obtained from the Genomics of Drug Sensitivity in
Cancer (GDSC) project[18], which contains response data of anti-cancer drugs used against numerous
cancer cell lines. Data from GDSC data set is given by a matrix ICCCLE ∈ Rd×c, where d is number
of drugs and c is number of cancer lines. The elements in this matrix are ln(IC50) , where IC50 is
the half maximal inhibitory concentration value of the drugs used against specific cancer cell lines.
We obtain molecular data of anti-cancer drugs from PubChem dataset with their unique PubChem ID
available from GDSC dataset. Eventually, we get 3358 pieces of drug response data in breast cancer
cell lines where gene expression data and molecular structure are available.
3.2 Gene expression VAE(GeneVAE)
Our aims to extract latent vectors from CCLE gene expression data, which will be fit into the combined
MLP drug prediction network. We use fully connected neural networks for forward propagation with
a batch-norm layer before activation.
h1 = f1(Batchnorm((W1G
T + b1)) (1)
f1 is the activation function (ReLU in our model), W1 is the weight matrix and b1 is the bias vector
at the first dense layer. Batch normalization is used to train our model more efficiently. Activation
function help filter out unimportant information. h1 is the output of the first layer in our MLP model.
We connect it to the second layer:
µg = f2(Batchnorm((W2h
T
1 + b2)) (2)
where f2 is the activation function , W2 is the weight matrix and b2 is the bias vector at the second
dense layer. σg is computed by another 2-layer MLP with the same architecture as µg . Latent vector
zg is randomly sampled from N (µg, σg).
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The decoder architecture is constructed by two dense layers with same output dimensions as the input.
The decoded gene expression is written as G’.
G
′
= f4(W
T
4 (f3(W
T
3 zg + b3) + b4) (3)
In this VAE, we need to compute reconstruction loss L(G,G′) and Kullback-Leibler(KL) divergence
loss KL(q(z)||p(z|x))[16], where p is posterior distribution and q is distribution of z.q(z) serves to
standard normal distribution in a variational autoencoder. The total loss can be written to:
L(p, q) = L(G,G′) +KL(q(z)||p(z|x)) (4)
We aim to reduce total loss until the loss converges.
In our model, both the encoder and the decoder are two-layer fully connected neural network. The
sizes of both encoder layers are set as 256, while the sizes of both decoder layers are set the same as
input data.
3.3 Junction tree VAE(JTVAE)
Graph encoder We take junction tree variational autoencoder (JTVAE) [1] as one of our encoding
model to represent drug’s latent space. We use a message passing network[1, 6] as a graph encoder.
Suppose there d ∈ R nodes in the graph. Each node u has the property of atom type. buv ∈ Rd×d
encodes the bond type between node u and node v. The matrix M tju ∈ Rd×d represents the message
passing from node j to node u in number of t iterations. M tju is set to 0 initially. Wvu , Wu, W
′
uv
are three weight matrices separately. With the knowledge of loopy belief propagation, we can achieve
the message passing embedding with a rectified linear unit from node u to v at time t as:
M(t)uv = σ(Wvu
∑
j∈N(v)\u
M
(t−1)
ju +Wuau +W
′
uvbuv) (5)
Getting the message from the neighborhood of node u, we can aggregate those message embedding
vectors with its atom type, which can be written in the summation form with a rectified linear unit as
following equation(2). Final graph representation is shown as LgG.
Lgu = σ(
∑
j∈N(v)
UjuM
T
ju +Uuau), L
g
G =
∑
i
Lgi /|V | (6)
Mean µG and variance σG can be computed from L
g
G by an affine layer. The graph latent vector zG
is sampled from N (µG,σG).
Tree encoder The architecture of tree encoder is based on Gated Recurrent Unit(GRU)[1, 30]. The
hidden state is L˜(t)ij ∈ Rd×d in this tree encoder model. It is used to reserve tree’s message passing
information from the moment t-1 together with the tree clusters {xi, i = 1, 2, ... ,d}.
L˜
(t)
ij = tanh(Wixi +
∑
k∈N(i)\j
r
(t)
ki  L(t−1)ki ) (7)
There are two kinds of gates in our tree encoder model, which are reset gate r(t)ki and update gate z
(t)
ij .
r
(t)
ki is used for calculating how much the system is going to reserve while z
(t)
ij is used for counting
the probability that how likely the system is going to update the message passing information at the
moment t. If the reset gate r(t)ki is set to 0, the element-wise multiplication in equation (3) will be
simplified to tanh(Wixi), which means that there’s no reserved message at the previous stage.
r
(t)
ki = σ(W
′
ixi +U
′
rL
(t−1)
ki ), z
(t)
ij = σ(W
′′
i xi +U
′′
rL
(t−1)
ij ) (8)
The total update function, which depends on the previous activation L(t−1)ij and candidate activation
L˜
(t)
ij can be writtern into the form of elment-wise multiplication.
L
(t)
ij = (1− z(t)ij ) L(t−1)ij + z(t)ij  L˜(t)ij (9)
We can get the tree’s latent representation of node u by aggregating its updated messages at the t-th
iteration(equation 9 ). zτG is calculated in the smiliar way as graph encoder do. Since the graph and
tree decoders’ structure in JTVAE is also based on GRU method, we will not discuss about it here but
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instead reference to raw paper of JTVAE [1].
Lτu = σ(W
oxi +
∑
k∈N(i)
UoL
(t)
ij ) (10)
3.4 Drug response prediction network
Since gene VAE and molecular VAE have been trained at this stage, we implement two multi-layer
perceptron (MLP) models to post-process the output of the two VAE models respectively, and then
build another MLP model to concatenate them and produce the final drug response prediction. The
input to the final MLP model is aall = [agene,adrug], where agene and adrug are outputs of the two
post-processing MLP models. Suppose agene ∈ Rd1 and adrug ∈ Rd2 , then aall ∈ Rd1+d2 , which
means that the total dimension of the input to the final MLP model is d1 + d2. Value of perceptrons
of the ith layer in the final MLP model is computed according to:
ai+1all = f
′
(W
′Taiall + b
′
) (11)
where W
′
is the weight matrix of a layer in the final MLP model and f
′
is a non-linear activation
function for which we choose PRelu in our model. The predicted IC50 is computed at the last layer
of the final MLP model:
IC50 = f
′
(W
′Tan−1all + b
′
) (12)
where n is the number of layers in the final MLP model.
In our model, both of the two post-processing MLP consist of 3-layer fully connected neural network.
Since the outputs of geneVAE and JTVAE are 256-dimension vectors and 56-dimension outputs
respectively, we set sizes of two post-processing MLP as (256, 256, 64) and (128, 128, 64). The
final combiner MLP is a 4-layer fully connected neural network with 128, 128, 64 units in its hidden
layers.
Baseline model We use Support Vector Regression (SVR) in substitute for MLP as our baseline
model, showing a convenient way to take advantage of machine learning methods to make drug
response prediction. We choose poly kernel in our SVR model and set the parameter C as 10.
4 Experiments
Experiment set-up We first train our gene expression VAE(geneVAE) model and Junction Tree
VAE(JTVAE) unsupervisedly. Then we use geneVAE to encode gene expression data either filtered
by CGC data set or not respectively on breast cancer cell lines, and use Junction Tree VAE(JTVAE)
to encode anti-cancer drugs. With these encoded features, we train our Support Vector Regression
(SVR) and Multi-Layer Perceptron (MLP) model on breast cancer cell lines. Finally, we generalize
our model and test it on pan-cancer cell lines. Training set and test set are split by 9:1 for SVR
models, while training set, validation set and test set are split by 18:1:1 for MLP models.
4.1 Pre-training geneVAE
We aim to minimize sum of reconstruction loss and latent loss when training geneVAE model.
The reconstruction loss is L(G,G′), where G represents initial input gene expression data and
G’ represents reconstructed data. It can be mean squared loss[MSEloss] or cross entropy
loss[CrossEntropyloss]. We choose cross entropy loss as our reconstruction loss in our ex-
periments, because we normalize the input data add sigmoid function in the last layer to make sure
the input and output both consist of values between 0 and 1. We connect the input layer to the final
custom variational layer in our program to compute such loss.
Filtering out a representative gene subset using CGC data set also matters in the training of our
gene expression VAE model. We have mentioned in the 3.1 part that for breast cancer cell lines,
the selected gene number from CGC is 597. We test our model either filtering out a gene subset or
not on breast cancer cell lines, and the result indicates that filtering out such a gene subset could
help improve the accuracy of the prediction of IC50 value. According to the evaluation of total loss,
our tests show that at the beginning of the training loop, validation VAEloss is much higher than
training VAEloss, and VAEloss starts to convergent after 100 epochs. Model on CGC-selected gene
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expression data has an average VAEloss of 27.3. Model without CGC selected gene expression data
has an average VAEloss of 68 after validation loss becomes stable.
Figure 4: KLloss and lr with CGC Figure 5: KLloss and lr without CGC
4.2 Results on breast cancer
We propose several models and test them on breast cancer cell lines, and the results show that VAE
and CGC datasets contribute to more accurate predictions. We select 2 metrics: Coefficient of
Determination (R2 score) and Root Mean Square Error (RMSE) to evaluate the discrepancy between
our predicted drug response and true drug response. We propose 6 models and the results have been
listed in Table 1. Among these models, the first 5 models are targeted on breast cancer, and the last
one is tested on pan cancer cell lines: 1)CGC+ SVR : Support Vector Regression model trained
on drug molecular structure data encoded by VAE model and gene expression data filtered by CGC
dataset. 2)CGC+VAE+ SVR : Support Vector Regression model trained on gene expression
data filtered by CGC dataset and drug molecular structure data which are both encoded by VAE model.
3)CGC+MLP : Multi-Layer Perceptron model trained on drug molecular structure data encoded
by VAE model and gene expression data filtered by CGC dataset. 4)RAW +VAE+MLP :
Multi-Layer Perceptron model trained on raw gene expression data (not filtered by CGC dataset) and
drug molecular structure data which are both encoded by VAE model. 5)CGC+VAE+MLP :
Multi-Layer Perceptron model trained on gene expression data filtered by CGC dataset and drug
molecular structure data which are both encoded by VAE model. 6)CGC+VAE+MLP : Multi-
Layer Perceptron model trained on gene expression data filtered by CGC dataset and drug molecular
structure data which are both encoded by VAE model. This model is trained on pan cancer dataset.
The test results of these models are shown in Table 1. We can see that the MLP model and VAE
model bring about huge improvement in the performance of our models: CGC+MLP : model
outperformsCGC+ SVR : model by 0.143 R2 score, and CGC+VAE+MLP : model per-
forms even better than CGC+MLP : model with a 0.008 higher R2 score. Moreover, the se-
lection of representative gene subset is essential to the performance of our models. For example,
CGC+VAE+MLP : model on breast cancer cell lines reaches 0.830 R2 score, much better than
that of RAW +VAE+MLP : model with a 0.025 higher R2 score.
Table 1 Metrics evaluation on different gene subsets in breast cancer dataset(average).
Models Cancer type R2test RMSEtest
CGC + SVR Breast 0.658 1.582
CGC + VAE + SVR Breast 0.692 1.491
CGC + MLP Breast 0.822 1.133
RAW + VAE + MLP Breast 0.805 1.163
CGC + VAE + MLP Breast 0.830 1.130
CGC + VAE + MLP Pan-cancer 0.845 1.080
4.3 Generalization on pan-cancer
We generalize our model on the pan-cancer cell lines based on CCLE dataset. The only difference
in pan-cancer gene expression data from that of breast cancer is that the total number of pan-cancer
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Figure 6: CGC+SVR Figure 7: CGC+VAE+SVR Figure 8: CGC+MLP
Figure 9: Raw+VAE+MLP Figure 10: CGC+VAE+MLP Figure 11: CGC+VAE+MLP(pan)
cell lines is 1021. Our CGC+VAE+MLP model achieves an even higher R2score 0.845 on
pan-cancer cell lines. To make our model more robust, we will incorporate more data into our model
like TCGA dataset.
4.4 Exploring latent vectors from geneVAE
Taking advantage of the diversity of cancer types in pan-cancer dataset, we discover that latent
vectors encoded by geneVAE retains the features of original data. We visualize latent vectors of gene
expression data into two dimension Euclidean space. Effects of dimensionality reduction are evaluated
by a single t-SNE model compared with another t-SNE mdodel combined with our pretrained VAE
encoder. Generally t-SNE is just used for visualization on a two dimensional plane since t-SNE
model performs worse at a higher dimension space. We begin with giving each cell line its tissue type,
from "CERVIX" to "OVARY". We encode them by extracting the pattern after their first underscore
in CCLE dataset. Especially we rename "HAEMATOPOIETIC_AND_LYMPHOID_TISSUE" to
"HALT" since it’s the longest string. The parameters are perplexity and iterations for the single t-SNE
model. We set perplexity to n/120, where n are the numbers of cell lines and we set iterarions(n_iter
in python) to 3000. The same settings are applied to the combined model. The result shows that
many clusters are apparent both in a single t-SNE model and a combined model. Therefore, the latent
vectors encoded by geneVAE model retains the unique features of input data.
Figure 12: t-SNE on pancancer dateset before applying VAE
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Figure 13: t-SNE on latent vectors after applying VAE
In the single model, tissue type labels with [HALT], [AUTONOMIC_GANGLIA] ,[BREAST] and [SKIN]
etc are separate obviously, while some other type of tissues are clustered together with other similar
tissue types. For example, genes do not have a great difference on their expression according to
"STOMACH" and "LARGE INTESTINE". Several tissue types are so rare in cancer cell lines that
they might be clustered with another tissue, because t-SNE doesn’t exactly explain the real distance
between cancer types.
Eliminating rare cancer types could help improve the t-SNE results. We set the threshold of 30 to
filter the tissue types, where 12 tissues are hold. They are [BREAST, CENTRAL_NERVOUS_SYSTEM,
FIBROBLAST, HALT, KIDNEY, LARGE_INTESTINE, LUNG, OVARY, PANCREAS, SKIN,
STOMACH, UPPER_AERODIGESTIVE_TRACT]. We remain the gene subset that we have filtered and
eliminated from raw data. We visualize it again and find that more clusters are apparent in the picture,
where we use black frames to represent. The clustering results of latent vectors and original data
still remain similar in Figure 14, where primary cancer tissue types are separated clearly. Therefore,
latent vectors encoded by geneVAE model retain the essential features of original data robustly. With
geneVAE, our models are able to focus on the low-dimensional critical features of original data and
produce a more accurate prediction.
Figure 14: t-SNE with threshold 30 before and after VAE
4.5 Exploring latent vectors from JTVAE
Drugs sharing similar molecular structure are also similar in latent vectors. We get access to
latent vectors encoded by JTVAE, and reveal drugs sharing similar molecular structure are also
similar in latent vectors. We measure the similarity of latent vectors of different drugs in terms of
Euclidean Distance. Shorter distance indicates a higher similarity between two drugs. For example,
MG132(inhibitor) and Proteasome (inhibitor) share a shortest distance which is about 23.73. We
obtain their molecular structures in Pubchem database and find that a majority of functional groups
are similar between these two drugs. Small differences lie in a carboxyl and an amide at the endings
of the molecule. However, not all related drugs have such a great similarity. According to drug
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Imatinib and Linifanib, their are even closer in terms of Euclidean distance between their latent
vectors but they have only middle part of the functional groups exactly the same. JTVAE model
might discover underlying similarity among functional groups that are not exactly the same. Also,
the message passing network in JTVAE is based on GRU, and it might forget some functional groups
during propagation by neighbours.
Though similar drugs share close latent vectors, our MLP model is still able to capture subtle
differences and produce an accurate prediction. We focus on the example of MG132 and Proteasome
used against HCC1187 cancer cell line. We remove these two pieces of data from training set, and test
our trained model on them. The predicted IC50 of MG132 and Proteasome in cell line HCC1187 are
0.84 and -0.866 in our best model. True value of these two drugs are 1.589 and -0.181 respectively.
Although two values are not too close to the expected values, they do not step into the range of the
other’s confidence interval. Therefore, despite the considerably high similarity between similar drugs,
our MLP model is still able to differentiate each of them and produce a reasonable result.
Figure 15: Similar latent vectors on similar drug structures.
5 Discussion and conclusions
In this research we build gene expression VAE(geneVAE) model, junction tree VAE(JTVAE)model,
Support Vector Regression (SVR) model and several Multi-Layer Perceptron (MLP) models to
predict anti-cancer drug response. We extract latent vectors with geneVAE and JTVAE model to
fit them into our drug prediction network. We compare our combined models with baseline SVR
models to see their improvement in performance. Generally speaking, we have achieved a great
coefficient of determination value with our model (0.845 R2 score on pan-cancer and 0.830 on breast
cancer). Besides, we discuss the effectiveness of geneVAE and JTVAE model from the perspective of
visualization and drug similarity, further proving the validity of our pipeline.
There are still some interesting aspects that we have met during our research. Hyper-parameter tuning
and layer setting are superior. Different hyper-parameters lead to different consequence. For example,
adding Batch-Norm (BN) layer in MLP model results in a worse performance. Batch normalization
is a widely used technique to avoid gradient exploding and vanishing. However, its effectiveness is
doubtful when it is used in shallow networks with Rectified Linear Unit, where gradient exploding
and vanishing seldom occur. Moreover, the inconsistency among mini-batches could influence the
performance of the batch-norm layers badly. Besides BN layer, proportion of train-valid-test split
is essential to the final result, as well as the proportions of batch size and learning rate. We set
the default batch-size of 8 and learning rate 0.001 in the training loop. Larger values of these two
hyper-parameters convergent faster, however might meet with problem of falling into local minimum.
A proper proportion of train and validation and test sets are 10:1:1 and for each epoch we choose
them randomly from total dataset. K-fold cross validation is also a good choice.
We suggest dimensional reduction should be done without PCA, as well as t-SNE and some other
powerful clustering methods. PCA is not suitable when reducing dimension numbers to 56 or even
higher in our research. t-SNE is better than PCA at 2-dimensional representation. However we also
find that there are something mess up when applying t-SNE at 2-dimensional space. Besides, we will
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showcase more predictions in our future works with similar structure to further generalize our idea
that although similar, their latent vectors could not be changed when making predictions. Unless we
find the prediction value is not in each other’s confidence interval.
6 Future work
We have witnessed a great improvement of prediction accuracy by filtering out a gene subset with
CGC dataset. More promising methods in selecting a representative gene subset like network
propagation based on STRING could be used to further improve our model. Moreover, attention
mechanism based models are included in our future works. Using attention mechanism is not only
popular in transformer, BERT model which belong to natural language processing field, but also
widely used in drug structure translation field[12, 13]. Apart from attention based models, there are
other sequence generation models like GMM and graph neural network(GNN). Moreover, we’d like
to build a toolkit for drug response prediction if given one cancer cell line data and corresponding
drug’s response. Last but not least, select better gene subset of each drug since drug response may
have different gene contributions.
Acknowledgement
Thanks to professor Manolis Kellis for reviewing this artile.
References
[1] Wengong Jin, Regina Barzilay, and Tommi Jaakkola. Junction tree variational autoencoder for
molecular graph generation. arXiv preprint arXiv:1802.04364, 2018.
[2] Justin Gilmer, Samuel S Schoenholz, Patrick F Riley, Oriol Vinyals, and George E Dahl. Neural
message passing for quantum chemistry. arXiv preprint arXiv:1704.01212, 2017.
[3] Matt J Kusner, Brooks Paige, and José Miguel Hernández-Lobato. Grammar variational
autoencoder. arXiv preprint arXiv:1703.01925, 2017.
[4] Martin Simonovsky and Nikos Komodakis. Graphvae: Towards generation of small graphs
using variational autoencoders. In International Conference on Artificial Neural Networks,
pages 412–422. Springer, 2018.
[5] Qi Liu, Miltiadis Allamanis, Marc Brockschmidt, and Alexander Gaunt. Constrained graph
variational autoencoders for molecule design. In Advances in neural information processing
systems, pages 7795–7804, 2018.
[6] John R Hershey, Zhuo Chen, Jonathan Le Roux, and Shinji Watanabe. Deep clustering:
Discriminative embeddings for segmentation and separation. In 2016 IEEE International
Conference on Acoustics, Speech and Signal Processing (ICASSP), pages 31–35. IEEE, 2016.
[7] Yu-Chiao Chiu, Hung-I Harry Chen, Tinghe Zhang, Songyao Zhang, Aparna Gorthi, Li-Ju
Wang, Yufei Huang, and Yidong Chen. Predicting drug response of tumors from integrated
genomic profiles by deep neural networks. BMC medical genomics, 12(1):18, 2019.
[8] Jordi Barretina, Giordano Caponigro, Nicolas Stransky, Kavitha Venkatesan, Adam A Margolin,
Sungjoon Kim, Christopher J Wilson, Joseph Lehár, Gregory V Kryukov, Dmitriy Sonkin, et al.
The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature, 483(7391):603–607, 2012.
[9] Christopher H Grønbech, Maximillian F Vording, Pascal N Timshel, Capser K Sønderby, Tune H
Pers, and Ole Winther. scvae: Variational auto-encoders for single-cell gene expression datas.
bioRxiv, page 318295, 2018.
[10] Ladislav Rampasek, Daniel Hidru, Petr Smirnov, Benjamin Haibe-Kains, and Anna Goldenberg.
Dr. vae: Drug response variational autoencoder. arXiv preprint arXiv:1706.08203, 2017.
[11] Yoosup Chang, Hyejin Park, Hyun-Jin Yang, Seungju Lee, Kwee-Yum Lee, Tae Soon Kim,
Jongsun Jung, and Jae-Min Shin. Cancer drug response profile scan (cdrscan): a deep learning
model that predicts drug effectiveness from cancer genomic signature. Scientific reports,
8(1):1–11, 2018.
12
[12] Matteo Manica, Ali Oskooei, Jannis Born, Vigneshwari Subramanian, Julio Sáez-Rodríguez, and
Mariéa Rodriéguez Martiénez. Toward explainable anticancer compound sensitivity prediction
via multimodal attention-based convolutional encoders. Molecular Pharmaceutics, 2019.
[13] Ali Oskooei, Jannis Born, Matteo Manica, Vigneshwari Subramanian, Julio Sáez-Rodríguez,
and María Rodríguez Martínez. Paccmann: Prediction of anticancer compound sensitivity with
multi-modal attention-based neural networks. arXiv preprint arXiv:1811.06802, 2018.
[14] Masashi Tsubaki, Kentaro Tomii, and Jun Sese. Compound–protein interaction prediction with
end-to-end learning of neural networks for graphs and sequences. Bioinformatics, 35(2):309–
318, 2019.
[15] Laurens van der Maaten and Geoffrey Hinton. Visualizing data using t-sne. Journal of machine
learning research, 9(Nov):2579–2605, 2008.
[16] Diederik P Kingma and Max Welling. Auto-encoding variational bayes. arXiv preprint
arXiv:1312.6114, 2013.
[17] J M Lachlan and Tim J Hubbard. A census of human cancer genes. Nat Rev Cancer, 4(3):177–
183, 2004.
[18] Wanjuan Yang, Jorge Soares, Patricia Greninger, Elena J Edelman, Howard Lightfoot, Simon
Forbes, Nidhi Bindal, Dave Beare, James A Smith, I Richard Thompson, et al. Genomics of
drug sensitivity in cancer (gdsc): a resource for therapeutic biomarker discovery in cancer cells.
Nucleic acids research, 41(D1):D955–D961, 2012.
[19] Stephane Wenric and Ruhollah Shemirani. Using supervised learning methods for gene selection
in rna-seq case-control studies. Frontiers in genetics, 9:297, 2018.
[20] Shenghui Liu, Chunrui Xu, Yusen Zhang, Jiaguo Liu, Bin Yu, Xiaoping Liu, and Matthias
Dehmer. Feature selection of gene expression data for cancer classification using double
rbf-kernels. BMC bioinformatics, 19(1):1–14, 2018.
[21] Haiyan Huang and Kyungpil Kim. Unsupervised clustering analysis of gene expression. Chance,
19(3):49–51, 2006.
[22] Ladislav Rampášek, Daniel Hidru, Petr Smirnov, Benjamin Haibe-Kains, and Anna Golden-
berg. Dr. vae: improving drug response prediction via modeling of drug perturbation effects.
Bioinformatics, 35(19):3743–3751, 2019.
[23] David K Duvenaud, Dougal Maclaurin, Jorge Iparraguirre, Rafael Bombarell, Timothy Hirzel,
Alán Aspuru-Guzik, and Ryan P Adams. Convolutional networks on graphs for learning
molecular fingerprints. In Advances in neural information processing systems, pages 2224–
2232, 2015.
[24] Chris Dyer, Adhiguna Kuncoro, Miguel Ballesteros, and Noah A Smith. Recurrent neural
network grammars. arXiv preprint arXiv:1602.07776, 2016.
[25] Yujia Li, Oriol Vinyals, Chris Dyer, Razvan Pascanu, and Peter Battaglia. Learning deep
generative models of graphs. arXiv preprint arXiv:1803.03324, 2018.
[26] Vijil Chenthamarakshan, Payel Das, Inkit Padhi, Hendrik Strobelt, Kar Wai Lim, Ben Hoover,
Samuel C Hoffman, and Aleksandra Mojsilovic. Target-specific and selective drug design for
covid-19 using deep generative models. arXiv preprint arXiv:2004.01215, 2020.
[27] Kathleen M. Schmainda, Melissa Prah, Jennifer Connelly, Scott D. Rand, Raymond G. Hoffman,
Wade Mueller, and Mark G. Malkin. Dynamic-susceptibility contrast agent MRI measures of
relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.
Neuro-Oncology, 16(6):880–888, 01 2014.
[28] Takeshi Yuasa, Shunji Takahashi, Kiyohiko Hatake, Junji Yonese, and Iwao Fukui. Biomarkers
to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. Cancer
science, 102(11):1949–1957, 2011.
[29] Teruhiko Imamura, Koichiro Kinugawa, Shun Minatsuki, Hironori Muraoka, Naoko Kato,
Toshiro Inaba, Hisataka Maki, Taro Shiga, Masaru Hatano, Atsushi Yao, et al. Urine osmolality
estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to
tolvaptan in decompensated heart failure patients. Circulation Journal, 77(5):1208–1213, 2013.
[30] Junyoung Chung, Caglar Gulcehre, KyungHyun Cho, and Yoshua Bengio. Empirical evaluation
of gated recurrent neural networks on sequence modeling. arXiv preprint arXiv:1412.3555,
2014.
13
